Table 2.
Baseline characteristics of the subjects according to follow-up outcomes
| Variables | Subjects developed HTN (n = 2047) | Subjects did not develop HTN (n = 2639) | P |
|---|---|---|---|
| Gender (male/female, n) | 1541/506 | 1636/1003 | < 0.001 |
| Age (years) | 44.0(36.0–54.0) | 38.0(33.0–46.0) | < 0.001 |
| BMI (kg/m2) | 23.6(21.8–25.4) | 21.7(19.8–23.6) | < 0.001 |
| SBP (mmHg) | 124.0(117.0–131.0) | 112.0(105.0–120.0) | < 0.001 |
| DBP (mmHg) | 80.0(75.0–84.0) | 71.0(67.0–76.0) | < 0.001 |
| WC (cm) | 81.0(75.0–87.0) | 75.0(69.0–81.0) | < 0.001 |
| FLI | 22.0(9.2–41.6) | 8.03(3.63–19.96) | < 0.001 |
| BUN (μmol/L) | 5.09(4.29–5.96) | 4.86(4.15–5.66) | < 0.001 |
| Cr (μmol/L) | 74.0(64.0–83.0) | 71.0(60.0–80.0) | < 0.001 |
| FPG (mmol/L) | 4.53(4.21–4.89) | 4.37(4.09–4.66) | < 0.001 |
| UA (μmol/L) | 342.0(284.0–395.0) | 306.0(250.0–364.0) | < 0.001 |
| AST (U/L) | 20.0(17.0–25.0) | 19.0(16.0–23.0) | < 0.001 |
| ALT (U/L) | 25.0(17.0–37.0) | 20.0(15.0–30.0) | < 0.001 |
| y-GGT (U/L) | 21.0(15.0–34.0) | 16.0(11.0–24.0) | < 0.001 |
| TC (mmol/L) | 4.83(4.28–5.50) | 4.56(3.99–5.14) | < 0.001 |
| TG (mmol/L) | 1.38(1.01–2.02) | 1.07(0.80–1.51) | < 0.001 |
| HDL-C (mmol/L) | 1.26(1.07–1.52) | 1.27(1.08–1.58) | 0.020 |
| LDL-C (mmol/L) | 2.73(2.24–3.29) | 2.51(2.04–3.03) | < 0.001 |
| Apo-A1 (g/L) | 1.29(1.13–1.50) | 1.30(1.13–1.48) | 0.815 |
| Apo-B (g/L) | 0.97(0.81–1.14) | 0.85(0.71–1.01) | < 0.001 |
| eGFR (mL/(min·1.73 m2)) | 108.0(95.0–122.0) | 111.6(100.2–126.2) | < 0.001 |